Dianthus Therapeutics, Inc.: cashflow_investing
| Value | {"amount": 39995000, "concept": "us-gaap:NetCashProvidedByUsedInInvestingActivities", "currency": "USD"} |
|---|---|
| Period | 2023-01-01 – 2023-06-30 |
| Status | current |
| Entity | Dianthus Therapeutics, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T17:19:32.661739+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/2de9f01e-c648-4e7b-9b7c-b98e65e7d139
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0000950170-24-093948 · Open the official SEC filing →Retrieved: 2026-08-19T17:19:32.661739+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001690585/cashflow-investing/2023-06-30 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/2de9f01e-c648-4e7b-9b7c-b98e65e7d139
History
- supersedes {"amount": 45370000, "concept": "us-gaap:NetCashProvidedByUsedInInvestingActivities", "currency": "USD"} (evidence 0000950170-23-037605)